A
Aligos Therapeutics, Inc. (ALGS)
NCM – Real vaqt narxi. Valyuta: USD
6.47
+0.26 (4.19%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
6.47
+0.26 (4.19%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aligos Therapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, jigar va virusli kasalliklarda qondirilmagan tibbiy ehtiyojlarni qondirish uchun yangi davolash usullarini ishlab chiqishga qaratilgan. Uning preparat nomzodi, ALG‑055009, metabolik disfunksiya bilan bog'liq steatohepatit va semirishni davolash uchun 2a fazali klinik sinovda bo'lgan kichik molekulali THR-ß agonisti. Kompaniya, shuningdek, 2 B fazali klinik sinovda bo'lgan kapsid yig'ilish modulyatori pevifoskorvir natriyini; va koronavirusni davolash uchun 1 fazali klinik sinovni yakunlagan kichik molekulali ritonavir-siz pan-koronavirus proteaza inhibitörü ALG‑097558ni ishlab chiqadi. Kompaniya Emory universiteti; va Katholieke Universiteit Leuven bilan litsenziya va tadqiqot hamkorligi shartnomasini imzolagan. Aligos Therapeutics, Inc. 2018-yilda tashkil etilgan va Janubiy San-Fransisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. David B. Smith Ph.D. | Executive VP & Head of Chemical Operations |
| Dr. Kieron Wesson Ph.D. | Vice President & Head of Chemistry Manufacturing Controls |
| Dr. Lawrence M. Blatt MBA, Ph.D. | CEO, President & Chairman of the Board |
| Dr. Ramon Polo M.B.A., Ph.D., Pharm.D. | Senior VP & Head of Global Regulatory Affairs |
| Dr. Sushmita M. Chanda DABT, Ph.D. | Executive Vice President & Chief Development Officer |
| Dr. Tse-I Lin Ph.D. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 10-Q | algs-20260331.htm |
| 2026-04-29 | DEFA14A | d122092ddefa14a.htm |
| 2026-04-29 | ARS | d26899dars.pdf |
| 2026-04-21 | 8-K | d50981d8k.htm |
| 2026-04-14 | 8-K | d107028d8k.htm |
| 2026-03-05 | S-8 | d111225ds8.htm |
| 2026-02-04 | 8-K | d12642d8k.htm |
| 2025-11-06 | 10-Q | algs-20250930.htm |
| 2025-08-06 | S-8 | d25818ds8.htm |
| 2025-08-06 | 8-K | f8k_080625.htm |
| Senior VP of Early Compound Development & Belgian Site Head |
| Mr. James Hassard M.B.A. | Executive VP & Chief Commercial Officer |
| Mr. Nikhil Aneja | Principal Accounting Officer |
| Ms. Kristina Engeseth M.B.A. | Senior VP and Head of People & Culture |
| Ms. Laura Kavanaugh | VP & Head of Legal |